AMRI shareholders approve sale of company

Shareholders of Albany Molecular Research Inc. on Friday approved the sale of the pharmaceutical research company to affiliates of private-equity firms based in Chicago and Washington, D.C. The vote comes a little more than two months after the drug developer's board unanimously approved the sale of the AMRI to affiliates of The Carlyle Group and GTCR LLC. The private-equity firms have agreed to pay $21.75 per share, an equivalent of more than $900 million to purchase the Albany, New York, region's…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news